In silico repositioning of approved drugs against Schistosoma mansoni energy metabolism targets
Nenhuma Miniatura disponível
Data
2018
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Schistosomiasis is a neglected parasitosis caused by Schistosoma spp. Praziquantel is
used for the chemoprophylaxis and treatment of this disease. Although this monotherapy is
effective, the risk of resistance and its low efficiency against immature worms compromises
its effectiveness. Therefore, it is necessary to develop new schistosomicide drugs. How ever, the development of new drugs is a long and expensive process. The repositioning of
approved drugs has been proposed as a quick, cheap, and effective alternative to solve this
problem. This study employs chemogenomic analysis with use of bioinformatics tools to
search, identify, and analyze data on approved drugs with the potential to inhibit Schisto soma mansoni energy metabolism enzymes. The TDR Targets Database, Gene DB, Pro tein, DrugBank, Therapeutic Targets Database (TTD), Promiscuous, and PubMed
databases were used. Fifty-nine target proteins were identified, of which 18 had one or more
approved drugs. The results identified 20 potential drugs for schistosomiasis treatment; all
approved for use in humans.
Descrição
Palavras-chave
Citação
CALIXTO, Nicole Melo et al. In silico repositioning of approved drugs against Schistosoma mansoni energy metabolism targets. Plos One, San Francisco, v. 13, n. 12, e0203340, 2018. DOI: 10.1371/journal.pone.0203340. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC6312253/. Acesso em: 2 jun. 2025.